Sugi Predict

Sugi Predict / Compounds / SCHEMBL5082984

SCHEMBL5082984

SCHEMBL5082984

NC(CC(=O)N1CCCCC1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP7 Q9UHL4 1/20 0.56
▸ GRIK1 P39086 6/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ATM Q13315 1/20 0.43
▸ GRIA1 P42261 1/20 0.42
▸ GRIA2 P42262 1/20 0.42
▸ GRIA4 P48058 1/20 0.42
▸ GRIK3 Q13003 1/20 0.42
▸ GRIK5 Q16478 1/20 0.42
▸ DPP8 Q6V1X1 1/20 0.41
▸ GRIK2 Q13002 2/20 0.41
▸ GRM1 Q13255 1/20 0.41
▸ GRM2 Q14416 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240333 1.00 DPP7 (0.56) DPP7GRIK1ALDH1A1SMN1; SMN2ATM
SCHEMBL13585531 0.98 DPP7 (0.53) DPP7GRIK1ALDH1A1SMN1; SMN2ATM
SCHEMBL1768696 0.98 DPP7 (0.53) DPP7GRIK1ALDH1A1SMN1; SMN2ATM
SCHEMBL13584699 0.94 DPP7 (0.48) DPP7GRIK1ALDH1A1SMN1; SMN2ATM
SCHEMBL2236487 0.94 DPP7 (0.48) DPP7GRIK1ALDH1A1SMN1; SMN2ATM
SCHEMBL10111703 0.90 DPP7 (0.47) DPP7GRIK1GRIA1GRIA2GRIA4
SCHEMBL8232307 0.84 ATM (0.43) DPP7ALDH1A1SMN1; SMN2ATMDPP8
SCHEMBL27755153 0.84 ATM (0.43) DPP7ALDH1A1SMN1; SMN2ATMDPP8
SCHEMBL1768834 0.83 KMT2A (0.48) DPP7KMT2ATDP1L3MBTL1
SCHEMBL13585633 0.83 MEN1 (0.44) DPP7ALDH1A1SMN1; SMN2DPP8HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 — — CN claimed
EP-1976873-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS Brystol-Myers Squibb Company (US) 2008-10-08 — — EP claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 — — US claimed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 — — WO claimed
US-20240173309-A1 LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR JANSSEN RESEARCH & DEVELOPMENT, LLC 2024-05-30 — — US disclosed
US-9637520-B2 Template-fixed peptidomimetics with CXCR7 modulating activity POLYPHOR AG (CH) 2017-05-02 — — US disclosed
CN-102712676-B There is the peptidomimetic that the template of CCR10 antagonistic activity is fixing 波利弗尔股份公司 2016-10-26 — — CN disclosed
CN-102844327-B Template-fixed peptidomimetics with CXCR7 modulatory activity 波利弗尔股份公司 2016-10-26 — — CN disclosed
EP-2531520-B1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY POLYPHOR AG (CH) 2016-05-11 — — EP disclosed
US-20150307556-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY POLYPHOR AG (CH) 2015-10-29 — — US disclosed
US-9109009-B2 Template-fixed peptidomimetics with CXCR7 modulating activity POLYPHOR AG (CH) 2015-08-18 — — US disclosed
US-8754038-B2 Template-fixed peptidomimetics with CCR10 antagonistic activity POLYPHOR AG (CH) 2014-06-17 — — US disclosed
US-20130225506-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY POLYPHOR AG (CH) 2013-08-29 — — US disclosed
CN-102844327-A Template-fixed peptidomimetics with CXCR7 modulatory activity POLYPHOR AG 2012-12-26 — — CN disclosed
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY POLYPHOR AG (CH) 2012-11-08 — — US disclosed
CN-102712676-A Template-fixed peptidomimetics with CCR10 antagonistic activty POLYPHOR AG 2012-10-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP DPP7 18/4885GRIK1 1402/4885ALDH1A1 4570/4885
US-20240173309-A1 LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR IL23R, IL1RN, IL36G DPP7 331/4885GRIK1 1069/4885ALDH1A1 4010/4885
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY CCR10, CCR1, CCRL2 DPP7 1414/4885GRIK1 1536/4885ALDH1A1 3484/4885
US-20150307556-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY CXCR1, CXCL12, CXCR6 DPP7 166/4885GRIK1 2016/4885ALDH1A1 1674/4885
US-20130225506-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY CXCR1, CXCL12, CXCR6 DPP7 174/4885GRIK1 2104/4885ALDH1A1 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.